If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
312.00    0.00 (0.00%)
Bid:
310.00
Ask:
314.00
Spread: 4.00 (1.29%)
Market Cap: £39.59m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Relationship Agreement with Brave Bison

21 Apr 2026 07:01

RNS Number : 2072B
System1 Group PLC
21 April 2026
 

 

21 April 2026

 

System1 Group PLC (AIM: SYS1)

 ("System1", or "the Company", or "the Group")

 

Relationship Agreement with Brave Bison

 

Further to the announcement on 2 March 2026 in relation to Brave Bison Group plc ("Brave Bison") acquiring a 27.85 per cent. shareholding in System1, the Company announces that it has entered into a customary relationship agreement with Brave Bison (the "Relationship Agreement") which includes the opportunity for a representative of Brave Bison to be appointed as an observer to the Company's board of directors (the "Board").

 

The key terms of the Relationship Agreement are as follows:

· Brave Bison has a right to appoint an observer to attend Board meetings subject to the prior approval of the Board;

· Brave Bison shall not take any action that is intended to or has the effect of preventing the Board from operating independently of Brave Bison;

· Brave Bison shall not take any action that would prevent System1 from complying with its obligations under applicable laws including the AIM Rules for Companies, the UK Market Abuse Regulation and the Corporate Governance Code published by the Quoted Companies Alliance;

· All transactions and dealings between the Company and Brave Bison, or any of its associated undertakings, shall be effected on arm's length terms and on a normal commercial basis; and

· The Relationship Agreement contains terms governing the provision of information to Brave Bison by the Company and customary provisions regarding the protection of confidential information.

 

The Relationship Agreement will terminate if Brave Bison and its associated undertakings cease to hold, in aggregate, 17.5 per cent. of the voting rights attaching to the issued ordinary share capital of the Company.

 

Rupert Howell, Non-Executive Chair of System1 commented:

 

"The Board of System1 is committed to acting in the interests of all its shareholders and we welcome Brave Bison as a significant shareholder in the Company. After careful consideration, and in line with its robust governance practices, the Board concluded it to be in the best interests of all shareholders and stakeholders to enter into a suitable agreement with Brave Bison, fostering a constructive and transparent relationship." 

 

Oliver Green, Chairman of Brave Bison commented:

 

"We are pleased to formalise our relationship with System1, and we look forward to working constructively with the Board and management team."

 

For further information, please contact:

 

System1 Group PLC

via Alma

James Gregory, Chief Executive Officer

Chris Willford, Chief Financial Officer

Canaccord Genuity Limited (Nominated Adviser & Broker)

Tel: +44 (0)20 7523 8000

Simon Bridges / Andrew Potts / Harry Rees

Singer Capital Markets (Joint Broker) 

Tel: +44 (0) 20 7496 3000 

James Moat / James Fischer

Alma Strategic Communications 

Tel: +44 (0)20 3405 0205

Caroline Forde / Rebecca Sanders-Hewett / Robyn Fisher

System1@almastrategic.com 

 

About System1 Group plc

 

System1 is a marketing decision-making platform business, utilised by some of the world's largest brands, across 81 markets globally. Since 2000, System1 has helped marketers tap into consumers' emotions to predict and improve the commercial impact of ads and ideas. Drawing on the world's largest database of emotional norms, our advertising and idea tests measure emotion to give our customers the most accurate predictions of the business impact of creativity. We 'predict' (provide research results) and work with our customers and 'improve' (provide insight and consultancy on those results) advertising effectiveness, innovation effectiveness and brand effectiveness. 

 

We work for more than 500 customers, including 5 of the top 10 US and 8 of the top 10 UK advertisers. Customers include Pfizer, Amazon, TikTok, Sky, Lego, Pladis and Natura.

 

Further information on the Company can be found at www.system1group.com.

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 and as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBIGDSDUDDGLG
Date   Source Headline
2nd Jul 20267:00 amRNSNotice of Investor Presentation
1st May 20264:30 pmRNSHolding(s) in Company
21st Apr 20267:01 amRNSRelationship Agreement with Brave Bison
21st Apr 20267:00 amRNSQ4 and Full Year Trading Update
9th Apr 20267:00 amRNS-RLaunch of next evolution of Test Your Ad platform
30th Mar 20264:30 pmRNSHolding(s) in Company
30th Mar 20263:30 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTrading Update
16th Mar 20267:00 amRNSTrading Update
5th Mar 20263:15 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:15 pmRNSHolding(s) in Company
3rd Mar 20264:06 pmRNSBoard Change
2nd Mar 20261:39 pmRNSShareholder update & PDMR Dealing
2nd Mar 20267:00 amRNSDirectorate change
30th Jan 20261:00 pmRNSBoard Committee and Change of Role Update
20th Jan 20267:00 amRNSTrading Update
12th Jan 20264:45 pmRNSAppointment of Joint Corporate Broker
2nd Dec 20257:00 amRNSInterim Results
20th Nov 202511:45 amRNSHolding(s) in Company
24th Oct 20253:28 pmRNSHolding(s) in Company
22nd Oct 20257:00 amRNSTrading Update
14th Oct 20259:16 amRNSCapital Markets Day
6th Oct 20253:30 pmRNSDirector/PDMR Shareholding
30th Sep 20257:00 amRNSDirector/PDMR Shareholding - replacement
29th Sep 20255:48 pmRNSDirector/PDMR Shareholding
29th Sep 20251:27 pmRNSHolding(s) in Company
26th Sep 20252:29 pmRNSHolding(s) in Company
26th Sep 20257:00 amRNSDirector/PDMR Shareholding
24th Sep 20253:01 pmRNSResult of AGM
23rd Sep 20257:00 amRNSTrading Update
15th Sep 20251:00 pmRNSDirector/PDMR Shareholding
27th Aug 20254:51 pmRNSNotice of AGM
8th Aug 20254:35 pmRNSDirector/PDMR Shareholding
9th Jul 20257:00 amRNSDirector Role Change
9th Jul 20257:00 amRNSFinal Results
9th Jul 20257:00 amRNSTrading Update
4th Jul 202511:45 amRNSHolding(s) in Company
4th Jul 20257:00 amRNSHolding(s) in Company
16th Jun 20251:30 pmRNSHolding(s) in Company
14th May 20257:00 amRNSEstablishment of New Long-Term Incentive Plan
24th Apr 20251:53 pmRNSHolding(s) in Company
23rd Apr 20257:00 amRNSTrading Statement
23rd Jan 20257:00 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTrading Update
8th Jan 202510:15 amRNSHolding(s) in Company
3rd Dec 20247:00 amRNSInterim Results
28th Nov 20247:00 amRNSInterim Results Presentation
21st Nov 20243:31 pmRNSHolding(s) in Company
28th Oct 202410:15 amRNSDirector/PDMR Shareholding
23rd Oct 20247:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.